Terns Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Terns Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • Terns Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 4.57 %, a 4.39% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 4.57 -0.21 -4.39% Sep 30, 2024
Q2 2024 5.02 +0.31 +6.59% Jun 30, 2024
Q1 2024 5.08 +0.53 +11.7% Mar 31, 2024
Q4 2023 5.17 +0.53 +11.4% Dec 31, 2023
Q3 2023 4.78 -0.34 -6.64% Sep 30, 2023
Q2 2023 4.71 -0.32 -6.36% Jun 30, 2023
Q1 2023 4.54 -0.01 -0.22% Mar 31, 2023
Q4 2022 4.63 +0.17 +3.81% Dec 31, 2022
Q3 2022 5.12 -5.99 -53.9% Sep 30, 2022
Q2 2022 5.03 Jun 30, 2022
Q1 2022 4.55 Mar 31, 2022
Q4 2021 4.46 Dec 31, 2021
Q3 2021 11.1 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.